Eisai
European approval for novel Eisai epilepsy monotherapy
May 23, 2017Research and Development, Sales and Marketing Bial, Eisai, Zebinix, epilepsy
Eisai and Bial have revealed that their drug Zebinix (eslicarbazepine acetate) has been awarded marketing authorisation by the European Commission …
22 pharma companies join forces for global non-communicable disease initiative
January 18, 2017Research and Development BMS, Celgene, Eisai, Eli Lilly, GSK, J&J, JJ, MSD, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda
The World Economic Forum Annual Meeting in Switzerland has seen the launch of Access Accelerated, a global initiative consisting of …
Eisai & Clinigen to bring breast cancer drug to South Africa
December 1, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Clinigen, Eisai, South Africa, breast cancer
Eisai and Clinigen have formed a collaboration to deliver the former’s cancer treatment Halaven (eribulin) to women in South Africa …
AbbVie and Eisai celebrate approval of new Humira indication
September 28, 2016Research and Development, Sales and Marketing AbbVie, Eisai, Humira
AbbVie and Eisai have announced the Japanese approval of a new indication for the former’s anti-TNF-α monoclonal antibody formulation Humira …
EU approval for Eisai kidney cancer treatment
September 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Afinitor, Eisai, Kisplyx, Lenvima, everolimus
The European Commission has approved the use of Eisai’s Kisplyx (lenvatinib) for the treatment of renal cell carcinoma (RCC) following …
Eisai reveals new long-term seizure control data at ECE 2016
September 13, 2016Manufacturing and Production, Research and Development Eisai, epilepsy
Eisai has revealed new data on long-term seizure control in different seizure types at the 12th European Congress on Epileptology …
Top ten stories in the pharmaceutical industry this week
September 9, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, BMS, Celgene, Cloud Computing, Eisai, FDA, GSK, Halaven, Novartis, Novo Nordisk, Roche, Teva, agios, epipen, rheumatoid arthritis
It’s Friday, and that means it’s time for another run-down of the biggest stories on Pharmafile.com over the last week. …
Eisai “cannot understand” German agency’s recommendation to reject Halaven
September 6, 2016Manufacturing and Production, Research and Development Eisai, Germany, Halaven, IQWIG, german
Eisai has issued a statement to declare their “bewilderment” following a decision from the German Institute for Quality and Efficiency …
Evaluation of Eisai’s advanced thyroid cancer treatment blocked until 2018 in England
August 2, 2016Manufacturing and Production, Sales and Marketing CDF, Eisai, Lenvima, NHS, NICE, lenvatinib, thyroid cancer
Following negotiations between the NHS, NICE and Japanese pharmaceutical company Eisai, differentiated thyroid cancer (RAI-R DTC) drug lenvima (levatinib) has …
EMA recommends two new treatments for advanced kidney cancer
July 22, 2016Research and Development, Sales and Marketing EMA, Eisai, renal cell carcinoma
The European Medicines Agency (EMA) has recommended two new medicines for the treatment of advanced renal cell carcinoma, or kidney …
Eisai criticises NICE and CDF for rare cancer ‘black hole’ in England
July 8, 2016Medical Communications, Research and Development CDF, Eisai, NICE, black hole
Japanese pharmaceutical company Eisai (TYO: 4523) has issued a statement expressing its dismay that advanced thyroid cancer patients in England …
Eisai launches cancer drug Lenvatinib in Mexico
July 4, 2016Research and Development, Sales and Marketing Cancer, Eisai, Mexico, lenvatinib, product launch
Japanese drug firm Eisai Co (TYO: 4523) said it has launched its anticancer agent Lenvima (lenvatinib mesylate) in Mexico. Lenvima …
Eisai partners with Novartis in renal cell carcinoma collaboration
June 3, 2016Medical Communications, Sales and Marketing Afinitor, Eisai, Lenvima, Novartis, US, everolimus, lenvatinib mesylate
Eisai (TYO: 4523) has announced that it has entered into a partnership with Novartis Pharmaceuticals to collaborate on commercial and …
Eisai granted additional indication for Lenvima in renal cell carcinoma
May 16, 2016Sales and Marketing Eisai, additional indication, renal cell carcinoma
Eisai has announced that it has received approval from the US Food and Drug Administration (FDA) for an additional indication …
Eisai says European Commission backs Halaven to treat of advanced Liposarcoma in Europe
May 5, 2016Research and Development, Sales and Marketing EC, Eisai, US FDA, oncology, regulation, soft tissue sarcoma
The European Commission has backed marketing for the Japanese drug major Eisai’s (TYO: 4523) Halaven (eribulin) to treat advanced soft …
Latest content
Five Facts about cardiovascular disease
